1
|
Kasper S, Meiler J, Knipp H, Höhler T, Reimer P, Steinmetz H, Berger W, Linden G, Ting S, Markus P, Paul A, Dechêne A, Schumacher B, Kostbade K, Worm K, Schmid K, Herold T, Schuler M, Trarbach T. Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.56] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
2
|
Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, Chistyakov V, Höhler T, Kim JS, Hofheinz RD, Ackland SP, Swinson D, Kopp M, Udovitsa D, Hall M, Iveson T, Vogel A, Zalcberg JR. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol 2016; 27:1273-9. [PMID: 27091810 DOI: 10.1093/annonc/mdw176] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Accepted: 04/10/2016] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC. PATIENTS AND METHODS Patients with mCRC were randomized to receive first-line therapy with mFOLFOX6 plus aflibercept (4 mg/kg) or mFOLFOX6 alone. The primary end point of this phase II study was the progression-free survival (PFS) rate at 12 months in each arm. The analysis of efficacy between the arms was a pre-planned secondary analysis. RESULTS Of 236 randomized patients, 227 and 235 patients were evaluable for the primary efficacy analysis and safety, respectively. The probabilities of being progression-free at 12 months were 25.8% [95% confidence interval (CI) 17.2-34.4] for the aflibercept/mFOLFOX6 arm and 21.2% (95% CI 12.2-30.3) for the mFOLFOX6 arm. The median PFS was 8.48 months (95% CI 7.89-9.92) for the aflibercept/mFOLFOX6 arm and 8.77 months (95% CI 7.62-9.27) for the mFOLFOX6 arm; the hazard ratio of aflibercept/mFOLFOX6 versus mFOLFOX6 was 1.00 (95% CI 0.74-1.36). The response rates were 49.1% (95% CI 39.7-58.6) and 45.9% (95% CI 36.4-55.7) for patients treated with and without aflibercept, respectively. The most frequent treatment-emergent grade 3/4 adverse events (AEs) excluding laboratory abnormalities reported for aflibercept/mFOLFOX6 versus mFOLFOX6 were neuropathy (16.8% versus 17.2%) and diarrhea (13.4% versus 5.2%). Neutropenia grade 3/4 occurred in 36.1% versus 29.3%. The most common vascular endothelial growth factor inhibition class-effect grade 3/4 AEs for aflibercept/mFOLFOX6 versus mFOLFOX6 were hypertension (35.3% versus 1.7%), proteinuria (9.2% versus 0%), deep vein thrombosis (5.9% versus 0.9%) and pulmonary embolism (5.9% versus 5.2%). CONCLUSION No difference in PFS rate was observed between treatment groups. Adding aflibercept to first-line mFOLFOX6 did not increase efficacy but was associated with higher toxicity. CLINICAL TRIAL NUMBER NCT00851084, www.clinicaltrials.gov, EudraCT 2008-004178-41.
Collapse
Affiliation(s)
- G Folprecht
- Medical Department I, University Cancer Center, University Hospital Carl Gustav Carus, Dresden, Germany
| | - C Pericay
- Hospital de Sabadell, Corporació Sanitaria Parc Taulí-Institut Universitari, Sabadell, Spain
| | - M P Saunders
- Department of Radiotherapy and Oncology, The Christie NHS Foundation Trust, Manchester
| | - A Thomas
- Department of Cancer Studies, University of Leicester, Leicester, UK
| | - R Lopez Lopez
- Department of Medical Oncology, Hospital Clinico Universitario e Instituto de Investigación, Santiago de Compostela, Spain
| | - J K Roh
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
| | | | - T Höhler
- Department I of Internal Medicine, Prosper Hospital, Recklinghausen, Germany
| | - J-S Kim
- Department of Oncology and Hematology, Korea University Guro Hospital, Seoul, Republic of Korea
| | - R-D Hofheinz
- Department III of Internal Medicine, University Hospital, Mannheim, Germany
| | - S P Ackland
- Department of Medical Oncology, Calvary Mater Hospital, Newcastle Hunter Medical Research Institute and University of Newcastle, Callaghan, Australia
| | - D Swinson
- Department of Oncology, St James' Hospital, Leeds, UK
| | - M Kopp
- Samara Regional Oncology Dispensary, Samara
| | - D Udovitsa
- Oncological Dispensary #2, Sochi, Russia
| | - M Hall
- Cancer Services Division, Mount Vernon Cancer Centre, Middlesex
| | - T Iveson
- Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - A Vogel
- Clinic of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
| | - J R Zalcberg
- School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
| |
Collapse
|
3
|
Schulz H, Nietsch KH, Höhler T. Early detection of glucocorticoid-specific epidermal alterations using skin surface microscopy. Curr Probl Dermatol 2015; 21:132-9. [PMID: 8299366 DOI: 10.1159/000422372] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- H Schulz
- Dermatologische Praxis, Bergkamen, Frankfurt/Main, BRD
| | | | | |
Collapse
|
4
|
Élez E, Kocáková I, Höhler T, Martens UM, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csőszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol 2015; 26:132-140. [PMID: 25319061 DOI: 10.1093/annonc/mdu474] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Integrins are involved in tumour progression and metastasis, and differentially expressed on colorectal cancer (CRC) cells. Abituzumab (EMD 525797), a humanised monoclonal antibody targeting integrin αν heterodimers, has demonstrated preclinical activity. This trial was designed to assess the tolerability of different doses of abituzumab in combination with cetuximab and irinotecan (phase I) and explore the efficacy and tolerability of the combination versus that of cetuximab and irinotecan in patients with metastatic CRC (mCRC) (phase II part). METHODS Eligible patients had KRAS (exon 2) wild-type mCRC and had received prior oxaliplatin-containing therapy. The trial comprised an initial safety run-in using abituzumab doses up to 1000 mg combined with a standard of care (SoC: cetuximab plus irinotecan) and a phase II part in which patients were randomised 1 : 1 : 1 to receive abituzumab 500 mg (arm A) or 1000 mg (arm B) every 2 weeks combined with SoC, or SoC alone (arm C). The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included overall survival (OS), response rate (RR) and tolerability. Associations between tumour integrin expression and outcomes were also assessed. RESULTS Phase I showed that abituzumab doses up to 1000 mg were well tolerated in combination with SoC. Seventy-three (arm A), 71 (arm B) and 72 (arm C) patients were randomised to the phase II part. Baseline characteristics were balanced. PFS was similar in the three arms: arm A versus SoC, hazard ratio (HR) 1.13 [95% confidence interval (CI) 0.78-1.64]; arm B versus SoC, HR 1.11 (95% CI 0.77-1.61). RRs were also similar. A trend toward improved OS was observed: arm A versus SoC, HR 0.83 (95% CI 0.54-1.28); arm B versus SoC, HR 0.80 (95% CI 0.52-1.25). Grade ≥3 treatment-emergent adverse events were observed in 72%, 78% and 67% of patients. High tumour integrin αvβ6 expression was associated with longer OS in arms A [HR 0.55 (0.30-1.00)] and B [HR 0.41 (0.21-0.81)] than in arm C. CONCLUSION The primary PFS end point was not met, although predefined exploratory biomarker analyses identified subgroups of patients in whom abituzumab may have benefit. The tolerability of abituzumab combined with cetuximab and irinotecan was acceptable. Further study is warranted. CLINICALTRIALS.GOV IDENTIFIER: NCT01008475.
Collapse
Affiliation(s)
- E Élez
- Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - I Kocáková
- Department of Comprehensive Cancer Care, Masarykuv Onkologicky Ustav, Brno, Czech Republic
| | - T Höhler
- Medical Clinic I, Prosper-Hospital, Recklinghausen
| | - U M Martens
- Department of Hematology/Oncology, Cancer Center Heilbronn-Franken, Heilbronn
| | - C Bokemeyer
- Department of Oncology/Hematology, University Hospital Hamburg, Hamburg, Germany
| | - E Van Cutsem
- Department of Digestive Oncology, University Hospital Gasthuisberg Leuven and KULeuven, Leuven, Belgium
| | - B Melichar
- Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc
| | - M Smakal
- Department of Oncology, Horovice, Czech Republic
| | - T Csőszi
- Department of Oncology, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary
| | - E Topuzov
- GOU VPO St-Petersburg SMA, n/a Mechnikov Federal Agency of Healthcare, St Petersburg
| | - R Orlova
- City Clinical Oncology Dispensary, St Petersburg
| | - S Tjulandin
- S.I. Russian Cancer Research Center, Moscow, Russia
| | - F Rivera
- University Hospital Marques de Valdecilla, Santander, Spain
| | | | - R Bruns
- Merck KGaA, Darmstadt, Germany
| | | | - J Tabernero
- Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
| |
Collapse
|
5
|
Elez E, Kocáková I, Höhler T, Martens U, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Cso˝szi T, Vyushkov D, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J. Abituzumab Combined with Cetuximab Plus Irinotecan Versus Cetuximab Plus Irinotecan Alone, as Second-Line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: The Poseidon Phase I/Randomized Phase II Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu193.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C. [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol 2011; 49:461-531. [PMID: 21476183 DOI: 10.1055/s-0031-1273201] [Citation(s) in RCA: 151] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- M Moehler
- Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität, Langenbeckstraße 1, 55101 Mainz.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zubel A, Schmoll HJ. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008; 19:1442-1449. [PMID: 18441330 DOI: 10.1093/annonc/mdn150] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer. PATIENTS AND METHODS Cetuximab was administered weekly: 400 mg/m(2) initial dose, then 250 mg/m(2) and FUFOX: oxaliplatin 50 mg/m(2), FA 500 mg/m(2) and 5-FU as a 24-h infusion at either 1500 or 2000 mg/m(2) administered for 4 weeks followed by a 1-week rest (one cycle). RESULTS Dose-limiting toxicity (grade 3 diarrhea) occurred in 3 of 14 assessable patients receiving 5-FU at standard 2000 mg/m(2). This dose was administered to a further 25 patients. Cetuximab combined with FUFOX was generally well tolerated with the most common grade 3/4 adverse events being diarrhea (27%) and paresthesia (16%). The confirmed response rate for patients receiving 5-FU at standard 2000 mg/m(2) (N = 41) was 56%, with a median duration of 9.3 months. Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0-9.7) and 28.2 months, respectively. Cetuximab pharmacokinetics seemed not to be different for combination with FUFOX compared with cetuximab/irinotecan combinations. CONCLUSION This protocol is well tolerated and shows promising efficacy supporting further investigation.
Collapse
Affiliation(s)
- D Arnold
- Department of Oncology and Hematology, Martin-Luther-University Halle-Wittenberg, Halle
| | - T Höhler
- Johannes-Gutenberg University Hospital, Mainz, Germany
| | - C Dittrich
- ACR-ITR VIEnna and LBI-ACR VIEnna, Kaiser Franz Josef-Spital, Vienna, Austria
| | - F Lordick
- Klinikum rechts der Isar, Technische Universitaet, Muenchen
| | | | - J Riemann
- Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany
| | - E Wöll
- University Hospital Innsbruck, Innsbruck, Austria
| | - T Herrmann
- Department of Internal Medicine IV and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg
| | - A Zubel
- Clinical Research and Development, Merck KGaA, Darmstadt, Germany
| | - H-J Schmoll
- Department of Oncology and Hematology, Martin-Luther-University Halle-Wittenberg, Halle.
| |
Collapse
|
8
|
Höhler T, Kaluza W, Märker-Hermann E. Genetik der Spondylarthropathien. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Kaluza W, Höhler T, Märker-Hermann E. Genetische Aspekte und die Rolle von T-Lymphozyten in der Pathogenese der Arthritis psoriatica. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1043521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Wörns MA, Victor A, Galle PR, Höhler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels – a study in twins. Genes Immun 2006; 7:600-5. [PMID: 16900203 DOI: 10.1038/sj.gene.6364330] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Elevated baseline levels of acute-phase proteins such as C-reactive protein (CRP) or cytokines like interleukin-6 (IL-6) are known risk factors for atherosclerosis and cardiovascular disease (CVD) events. However, until today, there is only controversial information about the contribution of genetic and environmental factors. Therefore, we performed an open prospective study in 108 monozygotic (MZ) and 60 same-sex dizygotic (DZ) twin pairs to analyse the genetic and environmental contributions to plasma CRP and IL-6 levels. Heritability of IL-6 was 0.61, indicating that plasma IL-6 levels are to a major part influenced by genetic determinants; however, for CRP, heritability was only 0.22, pointing to a moderate genetic influence. Plasma CRP levels were strongly influenced by female gender, older age and especially the body mass index. Our data underline the central role of IL-6 in low-grade inflammation contributing to atherosclerosis and CVD.
Collapse
Affiliation(s)
- M A Wörns
- First Department of Internal Medicine, Johannes Gutenberg-University, Mainz, Germany
| | | | | | | |
Collapse
|
11
|
Ide MF, Dittmar M, Wurm M, Höhler T, Schneider PM, Kanitz M, Kahaly GJ. Specific genotype variations of Interleukin-10.G (IL-10.G) and MHC class I chain-related gene A (MICA) short tandem repeat polymorphisms in thyroid autoimmunity. Exp Clin Endocrinol Diabetes 2006. [DOI: 10.1055/s-2006-933033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
12
|
Dittmar M, Kaczmarczyk A, Bischofs C, Schneider PM, Höhler T, Kanitz M, Kahaly GJ. The TNF-alpha -308 A allele confers susceptibility to polyglandular autoimmunity. Exp Clin Endocrinol Diabetes 2006. [DOI: 10.1055/s-2006-933032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
13
|
Höhler T, Heike M, Lutz MP, Graeven U, Seufferlein T. [ASCO-Update 2005--Highlights of the 41st Meeting of the American Society of Clinical Oncology/ASCO 2005]. Z Gastroenterol 2005; 43:1253-9. [PMID: 16267711 DOI: 10.1055/s-2005-858746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Currently, the treatment of gastrointestinal cancers is rapidly changing due to the implementation of novel chemotherapeutic agents as well as the introduction of targeted therapies into treatment protocols. The following review provides an overview of the most important clinical trials in esophageal, gastric, colorectal, pancreatic and hepatobiliary cancer that were presented at the annual meeting of the American Society of Clinical Oncology.
Collapse
Affiliation(s)
- T Höhler
- Prosper Hospital Recklinghausen, Recklinghausen
| | | | | | | | | |
Collapse
|
14
|
Moehler M, Eimermacher A, Siebler J, Höhler T, Wein A, Menges M, Flieger D, Junginger T, Geer T, Gracien E, Galle PR, Heike M. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92:2122-8. [PMID: 15942629 PMCID: PMC2361806 DOI: 10.1038/sj.bjc.6602649] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m−2, LV 500 mg m−2, 24-h 5-FU 2000 mg m−2, and ELF comprised three once-daily doses of etoposide 120 mg m−2, LV 300 mg m−2, 5-FU 500 mg m−2. In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end point) were 30% for ILF and 17% for ELF (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.29–1.13, P=0.0766). Overall response rates over the entire treatment period for ILF and ELF were 43 and 24%, respectively (RR 0.56, 95% CI 0.33–0.97; P=0.0467). For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818). Both regimens were well tolerated, the main grade 3/4 toxicities being diarrhoea (18%, ILF) and neutropenia (57%, ELF). The data from this randomised phase II study indicate that ILF provides a better response rate than ELF, and that ILF should be investigated further for the treatment of metastatic gastric cancer.
Collapse
Affiliation(s)
- M Moehler
- Klinikum der Johannes-Gutenberg-Universität, Mainz, Dortmund, Germany
| | - A Eimermacher
- Klinikum der Johannes-Gutenberg-Universität, Mainz, Dortmund, Germany
| | - J Siebler
- Klinikum der Johannes-Gutenberg-Universität, Mainz, Dortmund, Germany
| | - T Höhler
- Klinikum der Johannes-Gutenberg-Universität, Mainz, Dortmund, Germany
| | - A Wein
- Universtitätsklinik Erlangen, Erlangen, Dortmund, Germany
| | - M Menges
- Universitätskliniken des Saarlandes, Homburg/Saar, Dortmund, Germany
| | - D Flieger
- Klinikum Aschaffenburg, Aschaffenburg, Dortmund, Germany
| | - T Junginger
- Klinikum der Johannes-Gutenberg-Universität, Mainz, Dortmund, Germany
| | - T Geer
- Diakonie Krankenhaus, Schwäbish Hall, Dortmund, Germany
| | - E Gracien
- Aventis Pharma Deutschland GmbH, Bad Soden/Ts
| | - P R Galle
- Klinikum der Johannes-Gutenberg-Universität, Mainz, Dortmund, Germany
| | - M Heike
- Med. Department Mitte, Klinikum Dortmund gGmbH, Beurhausstr. 10, Dortmund 44137, Germany
- Med. Department Mitte, Klinikum Dortmund gGmbH, Beurhausstr. 10, Dortmund 44137, Germany. E-mail:
| |
Collapse
|
15
|
Kaechele V, Seufferlein T, Höhler T, Möhler M, Lutz MP, Adler G. Oxaliplatin and paclitaxel in inoperable cancer of the esophagus and the gastro-esophogeal junction: Results of a phase I/II study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- V. Kaechele
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - T. Seufferlein
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - T. Höhler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - M. Möhler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - M. P. Lutz
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| | - G. Adler
- Univ Hosp, Ulm, Germany; Univ of Mainz, Mainz, Germany; Caritas Klin, Saarbrücken, Germany
| |
Collapse
|
16
|
Abstract
PURPOSE Analysis of the course of disease in patients with histologically proven HCC before and after orthotopic liver transplantation (LTx) who received transarterial chemoembolization (TACE). MATERIAL AND METHODS Thirty-five of a total collective of 363 patients with histologically proven HCC underwent LTx. Before LTx, all patients were treated with sequential TACE. According to treatment pattern, TACE should be performed every 6 weeks, using a suspension consisting of max. 10 mg Mitomycin C as well as 10 - 30 ml iodized oil (Lipiodol). Patients were classified according to the Milano criteria. Criteria were called exceeded if the tumor size was > 5 cm and/or > 3 tumors larger than 3 cm were found. Therapy success and liver function were examined by means of spiral CT and laboratory controls. Investigation parameters included the number of tumor knots as well as the maximum tumor size. Additionally, the Lipiodol accumulation, the patency of the portal vein and the occurrence of complications were checked. RESULTS Altogether, 184 TACE procedures were accomplished (5.3 +/- 3.3, range 1 - 14). The waiting period up to the transplantation amounted to 366 +/- 255 days (range 44 - 1137). The average number of tumor knots for each patient was 3.1 +/- 2.2 before and 2.9 +/- 2.2 after TACE (p = 0.887). The average tumor size was 4.2 +/- 2.5 before and 2.8 +/- 1.4 after TACE. The Milano criteria to LTx crossed 17/35 patients. Patients with exceeded Milan criteria showed a highly significant size reduction of the tumor after TACE (p = 0.001); in 9/17 cases the transplantation criteria were secondarily fulfilled through downstaging. A successful LTx was accomplished in 35/35 cases. Follow up after LTx was 769 +/- 509 days. The tumor recurrence in patients with exceeded vs. fulfilled transplantation criteria was 11.1 % vs. 11.8 % (p = 0.99). The recurrence free survival was 93.3 %, 82.5 % and 82.5 % at 1, 3 and 5 years, respectively. There were no relevant differences between patients with exceeded vs. fulfilled transplantation criteria (p = 0.99). CONCLUSION The sequential TACE is an effective method for the therapy of the HCC before LTx in selected patients. A relevant downsizing could be achieved by TACE in patients with advanced HCC. Patients with larger tumors showed a significantly stronger size reduction after TACE. The recurrence rate and the survival rate for patients with advanced or small tumors do not differ.
Collapse
Affiliation(s)
- S Herber
- Klinik und Poliklinik für Radiologie.
| | | | | | | | | | | | | |
Collapse
|
17
|
Dittmar M, Schneider PM, Höhler T, Wurm M, Kahaly GJ. MHC class I chain-related antigen A in mono- and polyglandular autoimmunity. Exp Clin Endocrinol Diabetes 2005. [DOI: 10.1055/s-2005-862921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Graeven U, Heike M, Höhler T, Lutz MP, Messmann H, Seufferlein T, Eberl T. [ASCO update -- highlights of the 40th Meeting of the American Society of Clinical Oncology/ASCO 2004]. Z Gastroenterol 2004; 42:1416-24. [PMID: 15592968 DOI: 10.1055/s-2004-813819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- U Graeven
- Krankenhaus St. Franziskus, Mönchengladbach
| | | | | | | | | | | | | |
Collapse
|
19
|
Heinemann V, Golf A, Seipelt G, Bauer J, Höhler T, Clemens M, Löhr JM, Stauch M, Lordick F, Hinke A. Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- V. Heinemann
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - A. Golf
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - G. Seipelt
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - J. Bauer
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - T. Höhler
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - M. Clemens
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - J. M. Löhr
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - M. Stauch
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - F. Lordick
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| | - A. Hinke
- University of Munich, Munich, Germany; Medical Oncology, Bad Soden, Germany; Clinic Nuremberg North, Nuremberg, Germany; Johannes-Gutenberg University, Mainz, Germany; Mutterhaus der Borromaerinnen, Trier, Germany; University of Mannheim, Mannheim, Germany; Medical Oncology, Kronach, Germany; University of Technology, Munich, Germany; WiSP, Langenfeld, Germany
| |
Collapse
|
20
|
Abstract
Over the last years the therapeutic possibilities for advanced gastric cancer have significantly increased. Here we discuss the new chemotherapeutic options and the existing results in palliative therapy.
Collapse
Affiliation(s)
- T Höhler
- 1. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz.
| | | |
Collapse
|
21
|
Dittmar M, Höhler T, Schneider PM, Adams P, Antunes C, Weber M, Kahaly GJ. Cytokine gene promoter polymorphisms in polyglandular autoimmunity. Exp Clin Endocrinol Diabetes 2004. [DOI: 10.1055/s-2004-819098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Eberl T, Graeven U, Heike M, Höhler T, Lutz MP, Messmann H, Seufferlein T. [ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003]. Z Gastroenterol 2003; 41:1039-45. [PMID: 14562203 DOI: 10.1055/s-2003-42922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- T Eberl
- Medizinische Klinik III, Klinikum Augsburg
| | | | | | | | | | | | | |
Collapse
|
23
|
Affiliation(s)
- M Holtmann
- 1st Department of Medicine, University of Mainz, Mainz, Germany
| | | | | | | | | | | | | |
Collapse
|
24
|
Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Höhler T. Differential regulation of interleukin-10 production by genetic and environmental factors--a twin study. Genes Immun 2002; 3:407-13. [PMID: 12424622 DOI: 10.1038/sj.gene.6363920] [Citation(s) in RCA: 184] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2002] [Revised: 07/07/2002] [Accepted: 07/09/2002] [Indexed: 12/13/2022]
Abstract
Interleukin-10 (IL-10) has a critical role in the regulation of immune responses. The relative contribution of genetic and environmental factors to IL-10 production is under debate. We performed a twin study in 246 monozygotic and dizygotic twins to assess the heritability of IL-10 production after LPS stimulation in whole blood. In addition, the influence of promoter single nucleotide polymorphisms (-1082, -819 and -592) on transcriptional activity and their binding to nuclear factors was studied in luciferase reporter gene and electrophoretic mobility shift assays. IL-10 production showed a genetic determination with a heritability of 0.5. Decreasing body mass index (BMI), smoking and female gender lead to decreased IL-10 production. In monocytes, the -1082A allele showed higher binding affinity to the transcription factor PU.1 resulting in decreased transcriptional activity of -1082A promoter haplotypes. Genetic determination of IL-10 secretion is probably lower than that previously reported. Fifty percent of the observed variability explained by genetic factors. Female individuals produce less IL-10 than male subjects. Environmental factors like smoking and decreasing BMI exert suppressing effects on IL-10 production. Although the -1082A allele shows higher binding affinity to the PU.1 transcription factor and lower transcriptional activity, this polymorphism probably explains only a small fraction of the observed heritability.
Collapse
Affiliation(s)
- E Reuss
- Department of Internal Medicine, Johannes Gutenberg-University, Mainz, Germany
| | | | | | | | | | | |
Collapse
|
25
|
Höhler T, Grossmann S, Stradmann-Bellinghausen B, Kaluza W, Reuss E, de Vlam K, Veys E, Märker-Hermann E. Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis. Ann Rheum Dis 2002; 61:213-8. [PMID: 11830425 PMCID: PMC1754040 DOI: 10.1136/ard.61.3.213] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To investigate the potential association of tumour necrosis factor alpha (TNFalpha) microsatellite and promoter alleles with psoriatic arthritis (PsA). METHODS DNA from 89 white patients with PsA, 65 patients with psoriasis, and 99 healthy white controls was investigated for two TNFalpha promoter (-238 and -308) and three microsatellite polymorphisms (TNFa, c, and d). Patients had previously been studied by serology for HLA class I antigens and by sequence-specific polymerase chain reaction for DRB1* alleles. In addition, TNFalpha production of Ficoll separated peripheral blood mononuclear cells (PBMC) into culture supernatants after stimulation with lipopolysaccharide, alphaCD3 antibodies, phytohaemagglutinin, and streptococcal superantigen C was determined. RESULTS A significant, HLA class I independent increase of the TNFa6c1d3 haplotype was found in the group with PsA but not among patients with psoriasis (32% v. 8%, pc<0.008; relative risk (RR)=5.3). In addition, patients with PsA showed a marked decrease of the TNF308A promoter allele (6% v. 18%; pc<0.008; RR=3.5) compared with healthy controls, which was independent of the increased frequency of the -238A polymorphism in this group. PBMC from patients with PsA secreted significantly less TNFalpha than cells from patients without arthritis. In particular, the TNFa6 microsatellite was associated with decreased TNFalpha production. CONCLUSION These data indicate that allelic variations at the TNFalpha locus influence susceptibility to PsA. Decreased production of TNFalpha is at least in part genetically determined and might be related to the development of arthritis. However, the association of the TNF308G allele with the disease also points to other disease related haplotypes with still unknown susceptibility genes.
Collapse
Affiliation(s)
- T Höhler
- I Medical Department, Johannes Gutenberg University, Mainz, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
In the last 2 years there has been considerable progress in investigating the genetic and immunologic background of psoriasis and psoriatic arthritis. This review focuses on genetics and the role of T-cells in the immunopathogenesis of the disease, with particular reference to psoriatic arthritis.
Collapse
Affiliation(s)
- T Höhler
- Medizinische Klinik und Poliklinik, Universität-Klinik, Mainz, Germany.
| | | |
Collapse
|
27
|
Abstract
Results of sibling and twin studies suggest that a substantial proportion of susceptibility to spondyloarthropathies arises from genes outside the human leukocyte antigen (HLA) region. There is increasing evidence that the pattern of cytokine secretion influences the course of spondyloarthropathies. A Th2 cytokine pattern (low tumor necrosis factor [TNF]-TNF-alpha low interferon [IFN]-gamma, and high interleukin [IL]-10) dominates in the joints of reactive arthritis patients. For IL-10 and TNF-alpha a substantial proportion of cytokine production is under genetic control and influenced by genetic polymorphisms. Here we review the evidences for association of TNF-alpha and IL-10 polymorphisms with spondyloarthropathies and their functional implications.
Collapse
Affiliation(s)
- M Rudwaleit
- Medizinische Klinik I, Universitätsklinikum Benjamin Franklin, Berlin, Germany
| | | |
Collapse
|
28
|
Kruger A, Quack P, Schneider PM, Rittner C, Höhler T. Sequence analysis of the DRB1 promoter reveals limited polymorphism with no influence on gene expression. Genes Immun 2001; 2:211-5. [PMID: 11477476 DOI: 10.1038/sj.gene.6363769] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2000] [Revised: 03/25/2001] [Accepted: 03/25/2001] [Indexed: 12/27/2022]
Abstract
HLA-class II promoters contain a set of conserved regulatory regions necessary for constitutive and induced gene expression. For the HLA-DQB as well as for the DRB1 promoter sequence, polymorphisms with influence on gene expression have been reported. In contrast to these data we could show that there is very limited allele-specific polymorphism among the HLA-DRB1 promoter alleles. In a long range PCR we amplified a DNA sequence containing the promoter and the second exon of the DRB1 gene in one fragment. Nested PCR products of this PCR fragment for the promoter and for the second exon were analysed by DNA sequencing to allow the linkage of a promoter to its DR allele. Most investigated DRB1 alleles exhibited the same promoter consensus sequence except for two point mutations. An A to T transversion (position -70 bp) was closely associated with DRB1*08, whereas a C-deletion (position -30 bp) was most commonly observed together with DRB1*10. Both polymorphisms did not influence promoter activity in luciferase reporter gene assays.
Collapse
Affiliation(s)
- A Kruger
- Institute of Legal Medicine, Johannes Gutenberg-University, Mainz, Germany
| | | | | | | | | |
Collapse
|
29
|
Thomssen H, Hoffmann B, Schank M, Höhler T, Thabe H, Meyer zum Büschenfelde KH, Märker-Hermann E. Cobalt-specific T lymphocytes in synovial tissue after an allergic reaction to a cobalt alloy joint prosthesis. J Rheumatol 2001; 28:1121-8. [PMID: 11361201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
Metals such as cobalt and nickel are common contact allergens. We studied the mechanisms underlying an allergic reaction with marked synovial inflammation in a patient with a cobalt alloy arthroplasty. After removing the joint prosthesis the adjacent synovial tissue was examined for cobalt-specific T lymphocytes. Synovial membrane mononuclear cells were expanded in interleukin 2 and cloned using a representative cloning protocol. T cell clones were tested for their proliferative response to cobalt and further characterized with regard to cytokine secretion, phenotype, and HLA restriction. Additionally, synovial fibroblasts were tested for their function as antigen presenting cells (APC). Almost 30% of the T cell clones reacted to cobalt, but not to the control nickel. All these T cell clones were CD4 positive. The cobalt induced proliferative response could be blocked by anticlass II antibodies. Also, synovial fibroblasts expressing class II molecules induced by interferon-gamma were able to serve as APC. However, when testing a panel of APC of HLA class II mismatched donors, no requirement for a certain HLA class II molecule could be defined. Further studies are necessary to determine mechanisms of presentation and recognition of cobalt by T lymphocytes, a prerequisite for improved prevention and treatment of metal induced allergic reactions.
Collapse
Affiliation(s)
- H Thomssen
- 1st Medical Department, University Hospital Mainz, Germany.
| | | | | | | | | | | | | |
Collapse
|
30
|
Duchmann R, Lambert C, May E, Höhler T, Märker-Hermann E. CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clin Exp Immunol 2001; 123:315-22. [PMID: 11207664 PMCID: PMC1905979 DOI: 10.1046/j.1365-2249.2001.01440.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Ankylosing spondylitis (AS) is a complex genetic disease in which both MHC and non-MHC genes determine disease susceptibility. To determine whether the T cell repertoires of individuals with AS show signs of increased stimulation by exogenous antigens, CD4+ and CD8+ T cell subsets of five monozygotic HLA-B27+ twins (two concordant and three discordant for AS) and CD8+ T cell repertoires of three healthy HLA-B27+ individuals were characterized by TCR beta-chain (TCRB) CDR3 size spectratyping. Selected TCRB-CDR3 spectra were further analysed by BJ-segment analysis and TCRB-CDR3 from expanded T cell clones were sequenced. In an analysis of all data (519/598 possible TCRB-CDR3 spectra), AS was associated with increased T cell oligoclonality in both CD8+ (P = 0.0001) and CD4+ (P = 0.033) T cell subsets. This was also evident when data were compared between individual twins. Nucleotide sequence analysis of expanded CD8+ or CD4+ T cell clones did not show selection for particular TCRB-CDR3 amino acid sequence motifs but displayed sequence homologies with published sequences from intra-epithelial lymphocytes or synovial T cells from rheumatoid arthritis patients. Together, these results provide support for the hypothesis that responses to T cell-stimulating exogenous or endogenous antigens are involved in the induction and/or maintenance of AS.
Collapse
Affiliation(s)
- R Duchmann
- Internal Medicine II, University of the Saarland, Hamberg. inrduc2med-rz.uni-sb.de
| | | | | | | | | |
Collapse
|
31
|
Kaluza W, Leirisalo-Repo M, Märker-Hermann E, Westman P, Reuss E, Hug R, Mastrovic K, Stradmann-Bellinghausen B, Granfors K, Galle PR, Höhler T. IL10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients. ACTA ACUST UNITED AC 2001; 44:1209-14. [PMID: 11352256 DOI: 10.1002/1529-0131(200105)44:5<1209::aid-anr205>3.0.co;2-s] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE To investigate the association of microsatellites and single-nucleotide promoter polymorphisms (SNPs) in the gene for the cytokine interleukin-10 (IL-10) with susceptibility to and outcome of reactive arthritis (ReA). METHODS From genomic DNA, IL-10 microsatellites G and R and IL-10 promoter polymorphisms at positions -1087 and -524 were typed by polymerase chain reaction, automated fragment length analysis, and restriction fragment digestion in 85 Finnish patients with ReA and 62 HLA-B27-positive Finnish controls. ReA patients had been followed up for 20 years. Genotypes and haplotypes of IL-10 were correlated with distinct features of the disease course, such as triggering agent, chronic arthritis, development of ankylosing spondylitis, and other chronic features. RESULTS There was a significant decrease in the promoter alleles G12 (allele frequency 0.206 versus 0.033; corrected P < 0.001, odds ratio 0.14) and G10 (0.183 versus 0.092; P < 0.05, odds ratio 0.44) in the ReA group compared with the HLA-B27-positive controls. Chronic arthritis developed significantly more frequently in the B27-positive subjects than in the B27-negative subjects (P < 0.05) as well as in patients with [corrected] the IL10.G8 allele. No associations were observed for either SNP or for the IL10.R microsatellite polymorphism. CONCLUSION IL10.G12 and G10 microsatellite alleles show a strong protective effect against the development of ReA in Finnish subjects. Since these polymorphic markers themselves do not have direct functional implications, they most likely mark promoter haplotypes with distinct functional properties, suggesting that differential production of IL-10 is an important susceptibility factor for the development of ReA.
Collapse
|
32
|
Höhler T, Leininger S, Köhler HH, Schirmacher P, Galle PR. Heterozygosity for the hemochromatosis gene in liver diseases--prevalence and effects on liver histology. Liver 2000; 20:482-6. [PMID: 11169063 DOI: 10.1034/j.1600-0676.2000.020006482.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
BACKGROUND/AIMS The effect of heterozygosity for the C282Y mutation in the HFE hemochromatosis gene on iron accumulation and disease progression in liver disease patients is unclear. METHODS We investigated the prevalence of this mutation in 531 patients and 205 healthy controls. In addition, we assessed the influence of the mutation on liver histology in 34 C282Y heterozygous and 124 age-, sex- and disease-matched controls without the mutation using the modified HAI and Chevallier score. RESULTS The highest prevalence of the C282Y mutation was observed in patients with autoimmune hepatitis (17.2%, p<0.01) compared to 6.4% in healthy controls. Heterozygotes with hepatitis C and B virus infection showed higher ferritin and hepatic iron concentrations than patients without the mutation. However, we did not detect significant differences in necroinflammatory or fibrosis scores between carriers of the mutation and controls. CONCLUSIONS There are marked differences in the prevalence of the C282Y mutation in patients with different liver diseases, with the highest prevalence rates in autoimmune hepatitis and PBC. However, the C282Y mutation alone only leads to a mild increase in iron accumulation in the majority of the patients, with the exception of H63D/C282Y compound heterozygotes. We found no evidence for more pronounced fibrosis in C282Y heterozygotes.
Collapse
Affiliation(s)
- T Höhler
- 1st Department of Internal Medicine, Johannes Gutenberg-University Mainz, Germany.
| | | | | | | | | |
Collapse
|
33
|
Höhler T, Wünschel M, Gerken G, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients. Exp Clin Immunogenet 2000; 15:130-3. [PMID: 9813410 DOI: 10.1159/000019064] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Variants of the mannose-binding lectin (MBL) have been shown to be associated with low serum concentrations of the protein and to predispose to bacterial, fungal and viral infections. A recent small study on 33 Caucasian patients had suggested that a mutation at codon 52 of the MBL gene is associated with chronic hepatitis B virus (HBV) infection. Exon 1 of the MBL gene was amplified by PCR in 61 patients with chronic HBV infection, 28 patients with acute infection and in 60 controls. MBL variants were detected by subsequent restriction enzyme digestion and agarose gel electrophoresis. The occurrence of the codon 52 mutation in patients with chronic HBV infection did not differ significantly from that in controls or patients with acute infection (9 vs. 7%), nor were there any significant differences for the codon 54 mutation. The frequency of MBL variants at codon 52 and 54 is not increased in patients with chronic HBV infection. Thus, the previously reported association of MBL deficiency with chronic HBV infection in adults could not be confirmed.
Collapse
Affiliation(s)
- T Höhler
- First Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
| | | | | | | | | | | |
Collapse
|
34
|
Abstract
More than 90% of patients with genetic hemochromatosis carry a characteristic mutation in the HFE-gene (C282Y). HFE modulates the iron uptake by the transferrin receptor. Duodenal crypt cells of HFE-knockout mice show low intracellular iron concentrations which lead to an upregulation of the divalent metal transporter and enhanced iron uptake by duodenal enterocytes. Heterozygosity for the C282Y mutation appears to alter the course of other liver diseases like porphyria cutanea tarda and nonalcoholic steatohepatitis.
Collapse
Affiliation(s)
- T Höhler
- 1. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz.
| | | |
Collapse
|
35
|
Höhler T, Lohse AW, Schirmacher P. Progressive focal nodular hyperplasia of the liver in a patient with genetic hemochromatosis--growth promotion by iron overload? Dig Dis Sci 2000; 45:587-90. [PMID: 10749337 DOI: 10.1023/a:1005413728101] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- T Höhler
- I. Department of Internal Medicine and the Institute of Pathology, Johannes Gutenberg University, Mainz, Germany
| | | | | |
Collapse
|
36
|
Köhler HH, Höhler T, Küsel U, Kirkpatrick CJ, Schirmacher P. Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report. Pathol Res Pract 1999; 195:509-13. [PMID: 10448668 DOI: 10.1016/s0344-0338(99)80055-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
A case of a 62-year-old patient with hereditary hemochromatosis is reported, who developed hepatocellular carcinoma (HCC) in the absence of cirrhosis and other potential risk factors for HCC. Occurrence of HCC in patients with genetic hemochromatosis and noncirrhotic liver is a rare event which has previously been described only six times and appears to be limited to male patients.
Collapse
Affiliation(s)
- H H Köhler
- Institute of Pathology, Johannes-Gutenberg-University, Mainz, Germany
| | | | | | | | | |
Collapse
|
37
|
Höhler T, Kriegsmann J, Laukhuf F, Meyer zum Büschenfelde KH, Wandel E. The lady with a history of blood transfusion who developed palpable purpura and microhaematuria. Nephrol Dial Transplant 1999; 14:2035-7. [PMID: 10462297 DOI: 10.1093/ndt/14.8.2035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- T Höhler
- I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, Germany
| | | | | | | | | |
Collapse
|
38
|
Affiliation(s)
- T Höhler
- Medical Department of Internal Medicine, Johannes Gutenberg Universität Mainz, Langenbeckstrasse 1, D-55101 Mainz, Germany
| | | | | |
Collapse
|
39
|
Höhler T, Hug R, Schneider PM, Krummenauer F, Gripenberg-Lerche C, Granfors K, Märker-Hermann E. Ankylosing spondylitis in monozygotic twins: studies on immunological parameters. Ann Rheum Dis 1999; 58:435-40. [PMID: 10381488 PMCID: PMC1752907 DOI: 10.1136/ard.58.7.435] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To examine immunological parameters that might explain disease discordance in monozygotic twin pairs with ankylosing spondylitis (AS). METHODS 11 monozygotic twin pairs (nine with AS, two with undifferentiated spondyloarthropathy) were investigated. The peripheral T cell receptor Vbeta repertoire was investigated using FACS analysis and 14 different Vbeta antibodies. In addition serum samples were tested for antibodies to Klebsiella pneumoniae, Streptococcus pyogenes, Candida albicans, Proteus mirabilis, and Escherichia coli. Peripheral blood lymphocyte reactivity against a number of bacteria was investigated by interferon gamma ELISPOT assays. RESULTS Twins suffering from AS showed cellular hyporeactivity against K pneumoniae, S pyogenes, C albicans in the ELISPOT assays compared with healthy twins. In contrast with the antibody data, where no significant differences were observed between the two groups, AS concordant twins showed the most pronounced differences in their Vbeta repertoire on CD4+ and CD8+ lymphocytes. CONCLUSIONS Cellular hyporeactivity of peripheral blood cells to bacterial antigens might reflect defective T cell responses allowing bacterial antigens to persist in diseased patients. There are probably other environmental factors that influence disease concordance.
Collapse
Affiliation(s)
- T Höhler
- Medical Department of Internal Medicine, Johannes Gutenberg Universität Mainz, Mainz, Germany
| | | | | | | | | | | | | |
Collapse
|
40
|
Knolle PA, Kremp S, Höhler T, Krummenauer F, Schirmacher P, Gerken G. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hepat 1998; 5:399-406. [PMID: 9857349 DOI: 10.1046/j.1365-2893.1998.00127.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Acute infection with hepatitis C virus (HCV) develops into a chronic hepatitis in about 50-70% of patients. Treatment of these patients with interferon-alpha (IFN-alpha) results in a sustained long-term response in only 15-20% but causes numerous unwanted side-effects in a higher percentage of patients. The aim of our study was to define host or viral parameters that would allow identification of responders and non-responders to IFN-alpha prior to the onset of treatment. We studied a group of 87 patients suffering from chronic hepatitis C who were treated with IFN-alpha. After long-term follow-up, 18 patients (21%) showed a sustained response to IFN-alpha therapy (normalization of serum transaminases and loss of viral RNA from serum) for up to 7 years after therapy had ceased. By univariate and multivariate analyses, no host factors were found to be predictive of response to therapy. Neither the degree of inflammation or fibrosis in liver biopsy samples obtained before treatment nor immunogenetic factors (major histocompatibility complex II haplotype and tumour necrosis factor-alpha promoter polymorphism) were associated with response to therapy. In contrast, viral parameters showed a strong association with response to therapy. HCV genotype 3 was found significantly more frequently in responders (P = 0.034), and mean HCV RNA concentration was lower in responders (3.1 x 10(4)) than in non-responders (2.5 x 10(5)) (P = 0.01). By multivariate analysis, both HCV genotype and HCV RNA concentration were independent predictors of response to therapy. However, exact prediction of response to treatment for an individual patient was not possible on the basis of pretreatment viral RNA concentration or viral genotype. The best association with response to therapy was found to be clearance of HCV RNA from serum 3 months after the start of treatment (32 of 34 partial and sustained responders vs 0 of 53 non-responders; P = 0.001). In conclusion, determination of pretreatment viral factors, but not host factors, was significantly correlated with treatment response but did not give an accurate prediction for patients, whereas clearance of HCV RNA from serum after 3 months of therapy was predictive of response to therapy.
Collapse
Affiliation(s)
- P A Knolle
- First Department of Medicine, Johannes Gutenberg Universität, Mainz, Germany
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
In the spondyloarthropathies human leukocyte antigen (HLA) B27 confers a strong genetic predisposition to the development and to the chronicity of disease after extra-articular infection with certain gram-negative bacteria. The close relationships between infection, HLA-B27, other genetic factors, and the host immune system, however, still are unexplained. HLA-B27-positive arthritis continues to be an area of intensive investigation in basic and clinical research. New animal models with HLA-B27 transgenic mice and rats, as well as recent developments in understanding the processes involved in signal transduction, cytokine production, and human T-lymphocyte activation, contribute to the development of new pathogenic models of the spondyloarthropathies. This article summarizes the current concepts of the cause and pathogenesis of the spondyloarthropathies resulting from studies of clinical materials. The host-microbial interplay in human disease, namely in bacteria-induced reactive arthritis, may eludicate principle disease mechanisms in acute disease and in the development of chronic autoimmune arthritis or ankylosing spondylitis.
Collapse
Affiliation(s)
- E Märker-Hermann
- First Department of Medicine, Johannes Gutenberg University of Mainz, Germany.
| | | |
Collapse
|
42
|
Höhler T, Schäper T, Schneider PM, Meyer zum Büschenfelde KH, Märker-Hermann E. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1998; 41:1489-92. [PMID: 9704649 DOI: 10.1002/1529-0131(199808)41:8<1489::aid-art20>3.0.co;2-5] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE To investigate the potential association of tumor necrosis factor alpha (TNFalpha) promoter alleles with ankylosing spondylitis. METHODS DNA from 141 HLA-B27 positive Caucasian patients with ankylosing spondylitis and 46 B27-positive and 99 B27-negative healthy Caucasian controls was investigated by polymerase chain reaction amplification of the TNFalpha promoter region and subsequent dot-blot analysis with allele-specific oligonucleotides. RESULTS There was a significant decrease in the promoter alleles TNF-238.2 and TNF-308.2 in the ankylosing spondylitis group (266 wild-type alleles, 16 variant alleles) compared with the B27-positive (75 wildtype promoter alleles, 17 variant alleles; P<0.0004) and the B27-negative (159 wild-type promoter alleles, 39 variant alleles; P< 0.00001) control groups. Positivity for the variant promoter alleles conferred protection and a relative risk of 0.3 to B27-positive individuals. CONCLUSION These data indicate that allelic variations in the TNFalpha promoter influence disease susceptibility in HLA-B27 positive individuals. This protective effect of variant promoter alleles could be related to differences in TNFalpha production or could reflect the association of different B27 haplotypes with ankylosing spondylitis.
Collapse
Affiliation(s)
- T Höhler
- Johannes Gutenberg Universität Mainz, Germany
| | | | | | | | | |
Collapse
|
43
|
Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998. [PMID: 9515764 DOI: 10.1002/(sici)1096-9071(199803)54:3<173::aid-jmv5>3.0.co;2-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Tumor necrosis factor alpha (TNF-alpha) is involved in the pathogenesis of chronic hepatitis C virus infection. The gene for TNF-alpha is encoded in the major histocompatibility locus (MHC). Two polymorphisms at positions -308 and -238 in the TNF-alpha promoter region might influence TNF-alpha expression. These promoter polymorphisms have been linked previously to a number of infectious diseases. TNF-alpha promoter polymorphisms at positions -238 and -308 were studied by DNA sequencing and sequence-specific oligonucleotide hybridization in 82 individuals with chronic hepatitis C and 99 control subjects. Subjects had been HLA class I and class II typed in a previous study. The frequency of the TNF238.2 promoter allele was significantly higher in the hepatitis C group (18.7%) compared to the controls (3.5%; P < 0.0001; pcorr < 0.009). No significant differences in the frequency of the TNF308.2 allele were observed between patients and controls. The increased frequency of the TNF238.2 allele could not be explained by linkage disequilibrium to HLA-B or -DR genes. These findings show an association between the TNF238.2 promoter variant and chronic active hepatitis C. They suggest that this polymorphism or a linked gene may be a host factor contributing to the development of chronic active hepatitis C.
Collapse
Affiliation(s)
- T Höhler
- I. Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany.
| | | | | | | | | | | |
Collapse
|
44
|
Höhler T, Meyer CU, Notghi A, Stradmann-Bellinghausen B, Schneider PM, Starke R, Zepp F, Sänger R, Clemens R, Meyer zum Büschenfelde KH, Rittner C. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 1998; 59:212-8. [PMID: 9568796 DOI: 10.1016/s0198-8859(98)00014-7] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Nonresponsiveness to HBsAg vaccination is observed in 5-10% of vaccine recipients and is possibly caused by a defect in the T helper cell compartment. The immune response to HBsAg is influenced by genes of the major histocompatibility complex. We have investigated MHC class I and class II antigens in 53 adult responders and 73 nonresponders. Results obtained in this first study were tested in a second study with 56 responders and 62 nonresponders from an infant vaccination trial. In addition, the peripheral Vbeta-chain T-cell receptor repertoire was investigated using monoclonal antibodies and flow-cytometry in 26 adult responders and 38 nonresponders. As previously reported, nonresponsiveness to HBsAg vaccination was associated with DRB1*3 and DRB1*7. In addition, DRB1*13 was significantly increased among vaccine responders (35.2% vs 5.4%;p < 0.0001) suggesting an immune response promoting effect for this allele whereas the closely related allele DRB1*14 was associated with nonresponse in the infant study. There was no evidence for a hole in the T cell receptor Vbeta repertoire. In conclusion, in agreement with results obtained in mice there appears to be a hierarchy of DRB1* genes in the HBsAg immune response. The possible differential association of DRB1*13 and DRB1*14 may allow the identification of differences between responsiveness and nonresponsiveness to a few amino acid differences in the beta1-domain of the class II heterodimer.
Collapse
Affiliation(s)
- T Höhler
- I. Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenefelde KH, Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111:579-82. [PMID: 9528902 PMCID: PMC1904884 DOI: 10.1046/j.1365-2249.1998.00534.x] [Citation(s) in RCA: 166] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Cytokines such as TNF-alpha and interferon gamma (IFN-gamma) are important for the elimination of infected hepatocytes during acute hepatitis B virus (HBV) infection. Two G versus A transitions in the TNF-alpha promoter region at positions -308 and -238 possibly influence TNF-alpha expression. We investigated these TNF-alpha polymorphisms in 71 patients with chronic HBV infection, in 32 subjects that had spontaneously recovered from acute HBV infection, and in 99 healthy controls. The -238 A promoter variant was present in 18 (25%) of 71 patients with chronic HBV infection compared with two (6%) of 32 subjects with acute infection (P<0.04), and seven (7%) of 99 controls (P<0.003). By contrast, the prevalence of the variant at position -308 was similar in all investigated groups. The observed differences could not be explained by linkage disequilibrium to HLA-B or -DRB1* alleles. These findings suggest an association between the TNF-alpha promoter polymorphism at position -238 and the development of chronic HBV infection. This promoter variant appears to be linked to defective viral clearance.
Collapse
Affiliation(s)
- T Höhler
- Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany
| | | | | | | | | | | |
Collapse
|
46
|
Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54:173-7. [PMID: 9515764 DOI: 10.1002/(sici)1096-9071(199803)54:3<173::aid-jmv5>3.0.co;2-2] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Tumor necrosis factor alpha (TNF-alpha) is involved in the pathogenesis of chronic hepatitis C virus infection. The gene for TNF-alpha is encoded in the major histocompatibility locus (MHC). Two polymorphisms at positions -308 and -238 in the TNF-alpha promoter region might influence TNF-alpha expression. These promoter polymorphisms have been linked previously to a number of infectious diseases. TNF-alpha promoter polymorphisms at positions -238 and -308 were studied by DNA sequencing and sequence-specific oligonucleotide hybridization in 82 individuals with chronic hepatitis C and 99 control subjects. Subjects had been HLA class I and class II typed in a previous study. The frequency of the TNF238.2 promoter allele was significantly higher in the hepatitis C group (18.7%) compared to the controls (3.5%; P < 0.0001; pcorr < 0.009). No significant differences in the frequency of the TNF308.2 allele were observed between patients and controls. The increased frequency of the TNF238.2 allele could not be explained by linkage disequilibrium to HLA-B or -DR genes. These findings show an association between the TNF238.2 promoter variant and chronic active hepatitis C. They suggest that this polymorphism or a linked gene may be a host factor contributing to the development of chronic active hepatitis C.
Collapse
Affiliation(s)
- T Höhler
- I. Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany.
| | | | | | | | | | | |
Collapse
|
47
|
Höhler T, Schäper T, Schneider PM, Krummenauer F, Rittner C, Meyer zum Büschenfelde KH, Märker-Hermann E. No primary association between LMP2 polymorphisms and extraspinal manifestations in spondyloarthropathies. Ann Rheum Dis 1997; 56:741-3. [PMID: 9496154 PMCID: PMC1752309 DOI: 10.1136/ard.56.12.741] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To investigate the potential role of the HLA-linked LMP2 (low molecular weight protein) gene polymorphisms in conjunction with DR4 and DR7 on extraspinal disease manifestations in HLA-B27 positive patients with spondyloarthropathy. METHODS 172 patients with spondyloarthropathy, 46 healthy, HLA-B27 positive blood donors, and 99 unrelated controls were typed for HLA-class I and II antigens. LMP2 alleles were determined by polymerase chain reaction and subsequent restriction enzyme digestion. RESULTS There were statistically non-significant increases of DR4 and DR7 in spondyloarthropathy subjects. However these differences did not relate to specific extraspinal manifestations. There were no significant differences in the LMP2 genotype distribution in the disease groups. All differences in LMP2 genotype frequencies disappeared when correcting for DR4, which was in linkage disequilibrium with the LMP2B allele. CONCLUSIONS There is no independent association between LMP2 genotypes and the occurrence of uveitis or peripheral arthritis in HLA-B27 positive subjects with spondyloarthropathy. DR4 and DR7 do not contribute to these disease manifestations.
Collapse
Affiliation(s)
- T Höhler
- I Medical Department, Johannes Gutenberg University Mainz, Germany
| | | | | | | | | | | | | |
Collapse
|
48
|
Höhler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, Meyer zum Büschenfelde KH, Märker-Hermann E. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109:562-5. [PMID: 9326391 DOI: 10.1111/1523-1747.ep12337469] [Citation(s) in RCA: 147] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Tumor necrosis factor-alpha is considered to be one of the important mediators in the pathogenesis of psoriasis. A strong association of juvenile onset psoriasis with the major histocompatibility complex encoded HLA-Cw6 antigen has been reported but it is unclear whether Cw6 itself or a closely linked gene is involved in the pathogenesis. This study has focused on the association of promoter polymorphisms of the major histocompatibility complex encoded tumor necrosis factor-alpha gene with psoriasis and psoriatic arthritis. Tumor necrosis factor-alpha promoter polymorphisms were sought by sequence-specific oligonucleotide hybridization and by direct sequencing in Caucasian patients with juvenile onset psoriasis and with psoriatic arthritis and in healthy controls. A mutation at position -238 of the tumor necrosis factor-alpha promoter was present in 23 of 60 patients (38%; p < 0.0001; p[corr] < 0.008) with juvenile onset psoriasis and in 20 of 62 patients (32%; p < 0.0003; p[corr] < 0.03) with psoriatic arthritis, compared with seven of 99 (7%) Caucasian controls. There was a marked increase of homozygotes for this mutation in the psoriasis group. Another mutation at position -308 was found in similar proportions of patients and controls. Our study shows a strong association of the tumor necrosis factor-alpha promoter polymorphism at position -238 with psoriasis and psoriatic arthritis. Our findings suggest that this promoter polymorphism itself or a gene in linkage disequilibrium with tumor necrosis factor-alpha predispose to the development of psoriasis.
Collapse
Affiliation(s)
- T Höhler
- I. Medical Department, Johannes Gutenberg Universität Mainz, Germany
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Höhler T, Gerken G, Notghi A, Knolle P, Lubjuhn R, Taheri H, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 1997; 27:259-64. [PMID: 9288598 DOI: 10.1016/s0168-8278(97)80169-9] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND/AIMS Chronic hepatitis C develops in more than 70% of hepatitis C virus infected subjects. Viral factors influence the disease course, but little is known about the importance of host factors. METHODS Frequencies of major histocompatibility complex (MHC) class I and class II antigens were analyzed in two groups of patients with chronic hepatitis C virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotyping was done by PCR based typing methods. RESULTS DRB1*0301 was found in 26 of 75 patients with chronic hepatitis C virus infection (34.7%) and in 12 of 101 control subjects (11.9%) (relative risk 3.9; p < 0.001). Homozygosity for this allele appeared to confer a stronger risk. In contrast, DRB1*1301 was detected in three subjects with persistent infection (4.0%) compared to 21 control subjects (20.8%) (relative risk 0.2; p < 0.008). This allele was linked with DQA1*0103, which was found in 10 patients (13.3%) compared to 34 control subjects (33.7%) (relative risk 0.31; p < 0.003). An even stronger protective effect was provided by the presence of DRB1*1301 and DQA1*0103 (relative risk 0.08; p < 0.005). These findings were confirmed in a second group of chronic hepatitis C virus infected patients. CONCLUSIONS The MHC class II allele DRB1*0301 appears to predispose to progression to chronic active hepatitis C, whereas the class II alleles DRB1*1301 and DQA1*0103 appear to provide protection against chronic active infection with hepatitis C virus.
Collapse
Affiliation(s)
- T Höhler
- Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Höhler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Löhr HF, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26:503-7. [PMID: 9075656 DOI: 10.1016/s0168-8278(97)80414-x] [Citation(s) in RCA: 130] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND/AIMS The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection. METHODS Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were determined by polymerase chain reaction based typing methods. RESULTS In the first study the class II allele HLA-DRB1*1301-02 was found in 4 of 70 subjects with chronic hepatitis B virus infection (5.7%) compared to 27 of 101 healthy controls (26.7%, relative risk 0.17; p=0.001; p(corr)=0.025). This protective effect of the DRB1*1301-02 allele was confirmed in the second study. Eight of 24 patients (33.3%) who cleared hepatitis B virus spontaneously were positive for DRB1*1301-02 (relative risk of developing chronic infection compared to chronic hepatitis B subjects 0.12; p=0.004). Subtyping confirmed that 1301 and 1302 were both decreased in frequency in patients with chronic hepatitis B. CONCLUSIONS The MHC class II allele DRB1* 1301-02 is associated with protection from chronic hepatitis B in Caucasian patients.
Collapse
Affiliation(s)
- T Höhler
- I. Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|